In this issue of Blood, Wechalekar and colleagues demonstrate the importance of treating all patients with amyloidosis, no matter how severe their situation is, because clinically important responses are seen. 1 They also identify the adverse prognostic impact of a systolic blood pressure of ,100 mm Hg. 1 T his article from the 4 largest amyloidosis centers in Europe is important because it reports on large numbers and reduces the referral biases that major medical centers see with these patients. Often, when patients present with advanced end-stage disease, they are not referred or do not survive to be seen in a center of expertise, and reported center outcomes are not reflective of an unselected population. Moreover, these patients are often excluded from clinical trials of therapy in amyloidosis. As a result, published phase 2 trials are not representative of the "realworld" situation with amyloidosis. 2 All patients in this report were cardiac stage III 3 defined by an amino-terminal fragment braintype natriuretic peptide (NT-proBNP) of .332 ng/L and a cardiac troponin T of .0.035 mg/L or a cardiac troponin I .0.1 mg/L. These patients do poorly in large part due to late diagnosis and an inability to aggressively treat patients with poor performance status. Patients with cardiac amyloidosis are often diagnosed late because the condition is a classic example of heart failure with preserved systolic function and normal ejection fraction. 4 Physical findings such as purpura and enlargement of the tongue (see figure) are useful when present but are generally absent in 85% of patients, so a high index of suspicion is required. A number of staging systems exist to help prognosticate outcomes in amyloidosis, most recently, a combination of cardiac biomarkers and the difference between involved and uninvolved immunoglobulin free light chains, a measure of tumor mass. 5 For patients with advanced cardiac failure, the severity of heart impairment eliminates the relevance of the free light chain from the statistical model. A systolic blood pressure of ,100 mm Hg, reflecting advanced stiffening of the heart, poor diastolic filling, and a reduced stroke volume, resulting in a reduced systolic blood pressure, carries paramount importance in predicting outcome. Even with the poor prognosis in this group, the overall hematologic response rate on an intent-to-treat basis was 33% with 12% complete responses. It appears that no patient with amyloidosis should be denied a trial of therapy. The number of patients in each treatment category does not allow selection of any superior therapy: patients responded to combinations of melphalan and dexamethasone; combinations using thalidomide; and combinations using either bortezomib, lenalidomide, or both. A small subset of responders may become suitable candidates for safe stem cell transplantation 6 with reported 10-year survivorship. 7 Hematologists that see patients with monoclonal gammopathy of undetermined significance must be on the lookout for amyloidosis, which can manifest as simple fatigue or weight loss and be misattributed to multiple myeloma, simply because the bone marrow shows 10% plasma cells. Over 25 years of monitoring, one-quarter of patients with monoclonal gammopathy of undetermined significance will develop a serious plasma cell proliferative disorder. What is often overlooked is that one-eighth of these patients, or ;3%, will develop light showing stimulation of human effector T cells by similar peptides will be required to confirm this hypothesis. Autoimmune TTP is caused by antibodies that bind to ADAMTS13 and neutralize its proteolytic activity. Most acquired TTP patients circulate antibodies that bind to the spacer domain of ADAMTS13, although antibodies with specificity for other regions, including the CUB domains, have also been identified in subsets of TTP patients. [6] [7] [8] Although T-cell and B-cell epitopes often occur in close proximity or even overlap, they can also be derived from spatially distant regions of a protein antigen. This is because the presentation of T-cell and B-cell epitopes to the immune system is fundamentally different. CD4 T-cell epitopes consist of peptides at least 9 to 16 residues in length derived from antigens such as ADAMTS13, which bind to the MHC Class II binding groove on antigen-presenting cells. The MHC Class II-peptide complex is presented to T-cell receptors on, presumably in the case of TTP, autoreactive T cells that escaped thymic deletion and subsequently became
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